Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate...

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Limited comparative studies exist for short-term androgen deprivation (STADT) plus high-dose radiotherapy (RT) versus RT alone in localized prostate cancer.
• The GETUG 14 study addresses this gap by comparing these two treatment modalities.

Purpose of the Study:

• To evaluate the efficacy and safety of combining STADT with high-dose RT compared to high-dose RT alone for localized prostate cancer.
• To assess disease-free survival (DFS), overall survival (OS), and toxicity profiles.

Main Methods:

• Randomized controlled trial (GETUG 14) involving 376 patients with localized prostate cancer.
• Patients were assigned to either high-dose RT (80 Gy) or STADT-RT (80 Gy plus 4 months of triptorelin and flutamide).
• Primary endpoint was DFS; secondary endpoints included OS, biochemical failure, metastasis failure, toxicity, and quality of life.

Main Results:

• At a median follow-up of 84 months, the 5-year DFS rate was significantly higher in the STADT-RT arm (84%) compared to the RT arm (76%).
• STADT addition reduced biochemical and metastasis failure but did not significantly impact overall survival.
• No significant differences in acute or late gastrointestinal (GI) or genitourinary (GU) toxicity were observed between the two arms.

Conclusions:

• Short-term androgen deprivation combined with high-dose radiotherapy is a well-tolerated and effective strategy for enhancing oncological outcomes in localized prostate cancer.
• This combined approach is particularly beneficial for patients with intermediate- or high-risk disease.